Loading...
Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is being investigated in two Phase III trials, AMBER (NCT02431247; treatment-naive adults) and EMERALD (NCT02269917; treatment-experienced, virologically suppressed adults). Week 48 AMBER and EMERALD resistance an...
Na minha lista:
Udgivet i: | AIDS Res Hum Retroviruses |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Artigo |
Sprog: | Inglês |
Udgivet: |
Mary Ann Liebert, Inc., publishers
2020
|
Fag: | |
Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6944133/ https://ncbi.nlm.nih.gov/pubmed/31516033 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/aid.2019.0111 |
Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|